Search research articles
Contact Us
Filters
Showing results (221-230 of 251) with videos related to
Page
of 26
Sort By:
Nature Communications
|
December 10, 2025
The PIK3CA/AKT pathway drives therapy resistance in rhabdomyosarcoma
Qiqi Yang, Yueyang Wang, Luis A Corchete Sanchez, et al.
Cancer Research
|
July 31, 2025
Hypoxia-Induced Creatine Uptake Reprograms Metabolism to Antagonize PARP1-Mediated Cell Death and Facilitate Tumor Progression in Hepatocellular Carcinoma
Rui-Zhe Li, Guo-Qiang Pan, Chen Xiong, et al.
Cell Death & Disease
|
August 25, 2025
Targeting FAM111B attenuates mitophagy and increases the sensitivity to lenvatinib treatment by increasing MFN2 stability in hepatocellular carcinoma
Yu-Chuan Yan, Li-Juan Shao, Guang-Xiao Meng, et al.
Journal of Cancer Research and Clinical Oncology
|
February 11, 2025
Comparison of tenofovir versus entecavir for preventing hepatocellular carcinoma in chronic hepatitis B patients: an umbrella review and meta-analysis
Shi-Jia Liu, Xiao Zhang, Lun-Jie Yan, et al.
Clinical and Experimental Medicine
|
November 17, 2022
Adverse events of immune checkpoint inhibitors in hepatocellular carcinoma: a systemic review and meta-analysis
Jin-Cheng Tian, Hui Liu, Lun-Jie Yan, et al.
International Immunopharmacology
|
December 2, 2022
Evaluating liver function and the impact of immune checkpoint inhibitors in the prognosis of hepatocellular carcinoma patients: A systemic review and meta-analysis
Bao-Wen Tian, Lun-Jie Yan, Zi-Niu Ding, et al.
Journal of Cancer
|
June 7, 2021
RECK expression is associated with angiogenesis and immunogenic Tumor Microenvironment in Hepatocellular Carcinoma, and is a prognostic factor for better survival
Zhao-Ru Dong, Zhi-Qiang Chen, Xiao-Yun Yang, et al.
Expert Review of Anticancer Therapy
|
April 16, 2024
The effect of age, sex, and eastern cooperative oncology group performance status on the efficacy and safety of immune checkpoint inhibitors in patients with hepatocellular carcinoma: a systematic review and meta-analysis
Cheng-Long Han, Bao-Wen Tian, Lun-Jie Yan, et al.
Immunotherapy
|
May 4, 2023
Identification of the most effective subgroup of advanced hepatocellular carcinoma from immune checkpoint blocker treatment: a meta-analysis
Hui Liu, Chun-Cheng Yang, Yun-Long Ma, et al.
Cancer Cell International
|
July 23, 2024
Correction: MALAT1/ mir-1-3p mediated BRF2 expression promotes HCC progression via inhibiting the LKB1/AMPK signaling pathway
Guang-Zhen Li, Guang-Xiao Meng, Guo-Qiang Pan, et al.
Page
of 26
Search research articles
Search
Showing results (221-230 of 251) with videos related to
Sort By:
Page
of 26
Nature Communications
|
December 10, 2025
The PIK3CA/AKT pathway drives therapy resistance in rhabdomyosarcoma
Qiqi Yang, Yueyang Wang, Luis A Corchete Sanchez, et al.
Cancer Research
|
July 31, 2025
Hypoxia-Induced Creatine Uptake Reprograms Metabolism to Antagonize PARP1-Mediated Cell Death and Facilitate Tumor Progression in Hepatocellular Carcinoma
Rui-Zhe Li, Guo-Qiang Pan, Chen Xiong, et al.
Cell Death & Disease
|
August 25, 2025
Targeting FAM111B attenuates mitophagy and increases the sensitivity to lenvatinib treatment by increasing MFN2 stability in hepatocellular carcinoma
Yu-Chuan Yan, Li-Juan Shao, Guang-Xiao Meng, et al.
Journal of Cancer Research and Clinical Oncology
|
February 11, 2025
Comparison of tenofovir versus entecavir for preventing hepatocellular carcinoma in chronic hepatitis B patients: an umbrella review and meta-analysis
Shi-Jia Liu, Xiao Zhang, Lun-Jie Yan, et al.
Clinical and Experimental Medicine
|
November 17, 2022
Adverse events of immune checkpoint inhibitors in hepatocellular carcinoma: a systemic review and meta-analysis
Jin-Cheng Tian, Hui Liu, Lun-Jie Yan, et al.
International Immunopharmacology
|
December 2, 2022
Evaluating liver function and the impact of immune checkpoint inhibitors in the prognosis of hepatocellular carcinoma patients: A systemic review and meta-analysis
Bao-Wen Tian, Lun-Jie Yan, Zi-Niu Ding, et al.
Journal of Cancer
|
June 7, 2021
RECK expression is associated with angiogenesis and immunogenic Tumor Microenvironment in Hepatocellular Carcinoma, and is a prognostic factor for better survival
Zhao-Ru Dong, Zhi-Qiang Chen, Xiao-Yun Yang, et al.
Expert Review of Anticancer Therapy
|
April 16, 2024
The effect of age, sex, and eastern cooperative oncology group performance status on the efficacy and safety of immune checkpoint inhibitors in patients with hepatocellular carcinoma: a systematic review and meta-analysis
Cheng-Long Han, Bao-Wen Tian, Lun-Jie Yan, et al.
Immunotherapy
|
May 4, 2023
Identification of the most effective subgroup of advanced hepatocellular carcinoma from immune checkpoint blocker treatment: a meta-analysis
Hui Liu, Chun-Cheng Yang, Yun-Long Ma, et al.
Cancer Cell International
|
July 23, 2024
Correction: MALAT1/ mir-1-3p mediated BRF2 expression promotes HCC progression via inhibiting the LKB1/AMPK signaling pathway
Guang-Zhen Li, Guang-Xiao Meng, Guo-Qiang Pan, et al.
Page
of 26